In a study conducted by Mingzhu et al. in endometrial cancer, the combined ratio of estrogen and progesterone receptors to Ki-67 and p53 expression levels ([ER + PR]/[P53 + Ki-67]) was shown to outperform single markers in predicting disease recurrence. This evidence concerns the gene TP53 and endometrial cancer.